SCM
BLCM

Suffolk Capital Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Suffolk Capital Management’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6,353
Closed -$784K – 151
2017
Q1 		$784K Sell
6,353
-1,901
-23% -$249K 0.1% 119
2016
Q4 		$1.12M Buy
8,254
+3,690
+81% +$655K 0.15% 120
2016
Q3 		$908K Buy
+4,564
New +$786K 0.13% 125

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Suffolk Capital Management's BLCM Position: Q2 2017 in Review

Suffolk Capital Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2017, closing a stake of 6,353 shares — an estimated $784K sold.

Suffolk Capital Management first reported a position in BLCM in Q3 2016 and held it in 3 quarters. The position peaked at $1.12M in Q4 2016. 84 funds tracked by Wall St. Rank hold BLCM as of Q2 2017.

  • Suffolk Capital Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Suffolk Capital Management sold 6,353 Bellicum Pharmaceuticals, Inc. shares in Q2 2017, an estimated $784K.
  • Suffolk Capital Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2016 and held it in 3 quarters.
  • Suffolk Capital Management's Bellicum Pharmaceuticals, Inc. position peaked at $1.12M in Q4 2016.
  • 84 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2017.

Based on Suffolk Capital Management's 13F filing for Q2 2017, filed 28 Jul 2017.